Article

Perioperative Methylprednisolone and Outcome in Neonates Undergoing Heart Surgery

Department of Pediatrics, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
PEDIATRICS (Impact Factor: 5.3). 02/2012; 129(2):e385-91. DOI: 10.1542/peds.2011-2034
Source: PubMed

ABSTRACT Recent studies have called into question the benefit of perioperative corticosteroids in children undergoing heart surgery, but have been limited by the lack of placebo control, limited power, and grouping of various steroid regimens together in analysis. We evaluated outcomes across methylprednisolone regimens versus no steroids in a large cohort of neonates.
Clinical data from the Society of Thoracic Surgeons Database were linked to medication data from the Pediatric Health Information Systems Database for neonates (≤30 days) undergoing heart surgery (2004-2008) at 25 participating centers. Multivariable analysis adjusting for patient and center characteristics, surgical risk category, and within-center clustering was used to evaluate the association of methylprednisolone regimen with outcome.
A total of 3180 neonates were included: 22% received methylprednisolone on both the day before and day of surgery, 12% on the day before surgery only, and 28% on the day of surgery only; 38% did not receive any perioperative steroids. In multivariable analysis, there was no significant mortality or length-of-stay benefit associated with any methylprednisolone regimen versus no steroids, and no difference in postoperative infection. In subgroup analysis by surgical-risk group, there was a significant association of methylprednisolone with infection consistent across all regimens (overall odds ratio 2.6, 95% confidence interval 1.3-5.2) in the lower-surgical-risk group.
This multicenter observational analysis did not find any benefit associated with methylprednisolone in neonates undergoing heart surgery and suggested increased infection in certain subgroups. These data reinforce the need for a large randomized trial in this population.

Download full-text

Full-text

Available from: Jennifer S Li, Jul 01, 2015
0 Followers
 · 
130 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac surgery with cardiopulmonary bypass (CPB) triggers a vigorous systemic inflammatory response characterized by early and late phases involving both the humoral and cellular pathways. Steroids dampen the immune response to CPB in a multimodal fashion. Perioperative steroid prophylaxis offers the possibility to manipulate the inflammatory response to CPB for outcome benefit. In adult cardiac surgery with CPB, steroids have been rigorously evaluated in multiple randomized clinical trials and meta-analyses. In summary, steroid therapy in this setting can significantly reduce perioperative morbidity. Although the outcome benefits of steroids in adult cardiac surgery with CPB are apparent, multicenter large randomized trials are in progress to determine whether these agents should become a routine component of an anti-inflammatory approach to optimize clinical outcome. The current application of steroids in adult CPB is highly variable, with the highest use likely in high-risk settings such as deep hypothermic circulatory arrest. In pediatric cardiac surgery with CPB, steroids are widely used despite a limited evidence base compared with adult CPB. Recent multicenter observational trials have paved the way for larger more definitive randomized trials targeted to high-risk pediatric CPB including the neonatal period. In conclusion, steroids offer significant potential to improve meaningful clinical outcomes after cardiac surgery with CPB. The results of 2 landmark multicenter randomized trials in adult CPB likely will determine whether steroids should become routine therapy in this setting. It is likely that similar multicenter trials in pediatric CPB will be launched in the near future.
    Journal of cardiothoracic and vascular anesthesia 07/2012; 26(5):952-8. DOI:10.1053/j.jvca.2012.05.001 · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Administrative datasets are often used to assess outcomes and quality in pediatric cardiac operations; however their accuracy regarding case ascertainment is unclear. We linked patient data (2004-2010) from the Society of Thoracic Surgeons Congenital Heart Surgery (STS-CHS) Database (clinical registry) and the Pediatric Health Information Systems (PHIS) database (administrative database) from hospitals participating in both to evaluate differential coding/classification of operations between datasets and subsequent impact on outcomes assessment. METHODS: Eight individual benchmark operations and the Risk Adjustment in Congenital Heart Surgery, version 1 (RACHS-1) categories were evaluated. The primary outcome was in-hospital mortality. RESULTS: The cohort included 59,820 patients from 33 centers. There was a greater than 10% difference in the number of cases identified between data sources for half of the benchmark operations. The negative predictive value (NPV) of the administrative (versus clinical) data was high (98.8%-99.9%); the positive predictive value (PPV) was lower (56.7%-88.0%). Overall agreement between data sources in RACHS-1 category assignment was 68.4%. These differences translated into significant differences in outcomes assessment, ranging from an underestimation of mortality associated with truncus arteriosus repair by 25.7% in the administrative versus clinical data (7.01% versus 9.43%; p = 0.001) to an overestimation of mortality associated with ventricular septal defect (VSD) repair by 31.0% (0.78% versus 0.60%; p = 0.1). For the RACHS-1 categories, these ranged from an underestimation of category 5 mortality by 40.5% to an overestimation of category 2 mortality by 12.1%; these differences were not statistically significant. CONCLUSIONS: This study demonstrates differences in case ascertainment between administrative and clinical registry data for children undergoing cardiac operations, which translated into important differences in outcomes assessment.
    The Annals of thoracic surgery 11/2012; 95(1). DOI:10.1016/j.athoracsur.2012.08.074 · 3.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Every year in the United States approximately 40,000 infants are born with congenital heart disease. Several of these infants require corrective or palliative surgery in the neonatal period. Mortality rates after cardiac surgery are highest amongst neonates, particularly those born prematurely. There are several reasons for the increased surgical mortality risk in neonates. This review outlines these risks, with particular emphasis on the relative immaturity of the organ systems in the term and preterm neonate.
    Pediatric Cardiac Surgery Annual of the Seminars in Thoracic and Cardiovascular Surgery 01/2013; 16(1):21-31. DOI:10.1053/j.pcsu.2013.01.007